Jafron Biomedical Co Ltd (300529) — Working Capital to Net Assets Ratio
Jafron Biomedical Co Ltd (300529) has a Working Capital to Net Assets ratio of 72.6% as of March 2026. Working capital of CN¥2.69 Billion (current assets of CN¥3.03 Billion minus current liabilities of CN¥348.56 Million) is measured against net assets of CN¥3.70 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is Jafron Biomedical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Jafron Biomedical Co Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Jafron Biomedical Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 72.6%, reflecting working capital of CN¥2.69 Billion against net assets of CN¥3.70 Billion CNY. Check Jafron Biomedical Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Jafron Biomedical Co Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Jafron Biomedical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 300529 market cap overview.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 69.6% | CN¥2.42 Billion | CN¥3.47 Billion | CN¥2.92 Billion | CN¥502.10 Million | ▲ +9.1 pp |
| 2024 | 60.5% | CN¥2.02 Billion | CN¥3.33 Billion | CN¥2.78 Billion | CN¥766.79 Million | ▼ -18.3 pp |
| 2023 | 78.7% | CN¥2.48 Billion | CN¥3.15 Billion | CN¥3.31 Billion | CN¥829.42 Million | ▲ +7.0 pp |
| 2022 | 71.7% | CN¥2.58 Billion | CN¥3.59 Billion | CN¥3.29 Billion | CN¥717.18 Million | ▼ -7.1 pp |
| 2021 | 78.9% | CN¥2.67 Billion | CN¥3.38 Billion | CN¥3.06 Billion | CN¥386.26 Million | ▲ +20.5 pp |
| 2020 | 58.4% | CN¥1.66 Billion | CN¥2.83 Billion | CN¥1.99 Billion | CN¥330.82 Million | ▼ -1.3 pp |
| 2019 | 59.8% | CN¥1.30 Billion | CN¥2.17 Billion | CN¥1.56 Billion | CN¥262.63 Million | ▲ +0.2 pp |
| 2018 | 59.6% | CN¥1.03 Billion | CN¥1.72 Billion | CN¥1.31 Billion | CN¥278.90 Million | ▼ -9.4 pp |
| 2017 | 69.0% | CN¥960.82 Million | CN¥1.39 Billion | CN¥1.23 Billion | CN¥269.84 Million | ▼ -8.2 pp |
| 2016 | 77.3% | CN¥914.91 Million | CN¥1.18 Billion | CN¥999.20 Million | CN¥84.29 Million | ▲ +22.1 pp |
| 2015 | 55.1% | CN¥311.03 Million | CN¥564.06 Million | CN¥400.19 Million | CN¥89.16 Million | ▼ -1.7 pp |
| 2014 | 56.9% | CN¥257.30 Million | CN¥452.42 Million | CN¥310.92 Million | CN¥53.62 Million | ▼ -8.0 pp |
| 2013 | 64.9% | CN¥246.63 Million | CN¥380.12 Million | CN¥299.92 Million | CN¥53.29 Million | ▼ -9.9 pp |
| 2012 | 74.8% | CN¥217.62 Million | CN¥290.84 Million | CN¥254.58 Million | CN¥36.95 Million | ▼ -9.7 pp |
| 2011 | 84.6% | CN¥182.30 Million | CN¥215.57 Million | CN¥210.83 Million | CN¥28.53 Million | — |